Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
- 160 Downloads
RPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. The purpose of this study was to evaluate the safety and pharmacokinetics of RPI.4610 in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
The study used a sequential treatment design evaluating a single dose level for all three drugs: paclitaxel 175 mg m−2 and carboplatin AUC=6 on day 1 of a 21-day cycle, and RPI.4610 100 mg m−2 day−1 beginning on day 8 and continuing daily thereafter. Pharmacokinetic samples were drawn on day 1 of courses 1 (chemotherapy alone) and 2 (chemotherapy+RPI.4610), and on day 8 of course 1 (RPI.4610 alone). Ratios were generated by comparing the pharmacokinetic parameters for the combination of carboplatin with paclitaxel when administered alone or together with RPI.4610.
Twelve patients were enrolled in this trial and received two to six courses of treatment each. The most common grade 3–4 toxicities were neutropenia (three patients), thrombocytopenia (three patients), pain (three patients), anemia (two patients) and fatigue (two patients). The ratio of the mean maximum plasma concentration (Cmax) for carboplatin when administered with paclitaxel alone versus when administered with paclitaxel and RPI.4610 was 1.07 (90% confidence interval, 0.77–1.37). Similarly, the ratio of the mean AUC0-last for carboplatin was 1.04 (0.73–1.35). For paclitaxel the ratio of the mean Cmax when administered with carboplatin alone versus with carboplatin and RPI.4610 was 1.17 (1.03–1.31), and the ratio of the mean AUC0–last was 1.17 (1.04–1.30). Objective tumor responses were observed and included one patient with a complete response (bladder cancer) and one patient with a partial response (esophageal cancer).
These results indicate that RPI.4610, carboplatin, and paclitaxel can be administered safely in combination without substantial pharmacokinetic interactions.
KeywordsANGIOZYME Carboplatin Paclitaxel Pharmacokinetics Ribozyme Vascular endothelial growth factor receptor Angiogenesis inhibitors
This trial was supported by Sirna Therapeutics, Chiron, and NIH Grant RR00095. We thank Drs Jordan D. Berlin and Bruce J. Roth (Vanderbilt-Ingram Cancer Center), Dr Andrew S. Pierson and Martha S. Persky, R.N. (University of Colorado Cancer Center) for managing all clinical aspects of some study patients. We are also grateful to Drs Gary S. Gordon and Vann P. Parker for their help in performing pharmacokinetic analyses.
- 5.Bauer J, Morrison B, Oates R et al (2003) ANGIOZYME and interferon-α2b synergistically inhibit tumor angiogenesis. Proc Am Assoc Cancer Res 44 (Abstr 1159)Google Scholar
- 9.Jackson E, Sweedler D, Hartsough K et al (2002) Assessment of pharmacokinetic drug interactions between carboplatin and ANGIOZYME in vivo. Proc Am Assoc Cancer Res 43 (Abstr 1927)Google Scholar
- 10.Margolin K, Gordon MS, Holmgren E et al (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19:851–856PubMedGoogle Scholar
- 15.Royer I, Alvinerie P, Armand JP et al (1995) Paclitaxel metabolites in human plasma and urine: identification of 6 alpha-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom 9:495–502PubMedGoogle Scholar
- 19.U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (1999) In vivo drug metabolism/drug interaction studies—study design, data analysis, and recommendations for dosing and labelingGoogle Scholar
- 20.Venook A, Hurwitz H, Cunningham C et al (2003) Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme) in combination with chemotherapy. Proc Am Soc Clin Oncol 22 (Abstr 1025)Google Scholar
- 21.Weng DE, Weiss P, Kellackey C et al (2001) Angiozyme pharmacokinetic and safety results: a phase I/II study in patients with refractory solid tumors. Proc Am Soc Clin Oncol 20 (Abstr 393)Google Scholar